WHNT

Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S.

Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9200651-thea-pharma-inc-launches-iyuzeh/ "The U.S. launch of ...
Business Wire

Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda ® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe

Aerie’s first product, Rhopressa ® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular ...
Nasdaq

Glenmark Pharmaceuticals Launches Latanoprost Ophthalmic Solution In The U.S.

(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...
Healio

TearClear initiates phase 3 trial of preservative-free latanoprost

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. TearClear has initiated a phase 3 trial evaluating ...
Business Wire

Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in ...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of ...
Monthly Prescribing Reference

Iyuzeh Approved for Patients With Open-Angle Glaucoma, Ocular Hypertension

Iyuzeh is a preservative-free prostaglandin F2α analogue. The Food and Drug Administration (FDA) has approved Iyuzeh ™ (latanoprost ophthalmic solution) 0.005% for the reduction of elevated ...
Healio

Adoption of ophthalmic biosimilars expected to remain slow

Please provide your email address to receive an email when new articles are posted on . Most of us are familiar with the different classes of eye drops. Eye drops are ...
Nasdaq

Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies ...